Status:
COMPLETED
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Renal Transplant
Autoimmune Diseases
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Rituximab (a monoclonal antibody raised against CD20) is used to treat various immune disorders. In some cases such as treatment of humoral acute rejection of renal transplant, thrombotic thrombocytop...
Detailed Description
Twenty patients will be enrolled: ten patients treated by rituximab and ten patients treated by rituximab and plasma exchange. The plasma concentration of rituximab and the efficacy of the treatment w...
Eligibility Criteria
Inclusion
- Patient who should be treated by rituximab for various autoimmune diseases or humoral acute rejection of renal transplant
- Patient older than 18 years old
- Patient who have signed the written informed consent form
Exclusion
- Patient presenting a contra indication to rituximab (hypersensitivity, active infection, severe cardiac failure (NYHA class IV))
- Blood sampling impossibility
- Pregnant or breasting women
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00820469
Start Date
September 1 2008
End Date
January 1 2010
Last Update
May 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Toulouse
Toulouse, France, 31000